So I wasn't that observant on the first go 'round when Hoffman made his presentation but I see now from the newsletter that the EIND patient was given 3 cycles of carboplatin + Keytruda (Pembro in the wainwright presentation) back in 2021, to little effect. Now that LL has been added in to the equation and PD-L1 is upregulated I sure do hope that the Merck folks are paying attention.

"hey, our stuff didn't do shit 4 years ago and now it appears to be working...you think we should tell someone higher up?"

"nahhhhhhh"

For those with industry experience, you think folks at BP are paying attention to this patient?